Geneva, Oct. 27 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134590) titled 'An Open-Label. vulticenter, Phase l Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and PreliminaryEficacy of PZH2113 Capsules in Subjects with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma, PredominantlyDiffuse Large B-Cell Lymphoma' on Oct. 16.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
Recurrent/refractory B-cell non-Hodgkin's lymphoma mainly characterized by diffuse large B-cell lymphoma
Intervention:
Part A1/A2: Dose escalation and dose expansion sections:PZH2113 capsules, preset with 6 dose group...